5-MeO-DMT vs MDMA
A side-by-side research comparison of 5-MeO-DMT and MDMA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-MeO-DMT | MDMA |
|---|---|---|
| Full name | 5-Methoxy-N,N-dimethyltryptamine | 3,4-Methylenedioxymethamphetamine |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule I (FDA Breakthrough Therapy for PTSD) |
| Mechanism | Strongly activates serotonin 5-HT1A and 5-HT2A receptors, producing rapid and intense changes in consciousness. | Triggers large releases of serotonin (and to a lesser extent dopamine and norepinephrine) and increases oxytocin, prolactin and cortisol. This produces feelings of trust, openness and emotional closeness that support psychotherapy. |
| Molecular weight | 218.30 g/mol | 193.25 g/mol |
| Half-life | Short (minutes) | ~7-9 hours |
| Bioavailability | Inhaled/injected | Oral, high |
| Typical dose | Low milligram range in clinical studies | 75-125 mg (often with an optional supplemental half-dose) |
| Frequency | One to a few supervised sessions | A small number of monthly sessions |
| Route | Inhalation or injection in research settings | Oral, in a supervised therapeutic setting |
5-MeO-DMT reported benefits
- Studied for treatment-resistant depression
- Short duration suits clinical use
- Explored for anxiety
- Rapid onset of effects
MDMA reported benefits
- Studied for treatment-resistant PTSD
- Lowers fear response during trauma processing
- Increases trust and emotional openness
- Strong Phase 3 trial results from MAPS
Related comparisons
Research and educational reference only. Not medical advice.